EAM Investors LLC reduced its position in shares of Haemonetics Co. (NYSE:HAE) by 7.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,527 shares of the medical instruments supplier’s stock after selling 2,701 shares during the period. Haemonetics makes up 0.6% of EAM Investors LLC’s portfolio, making the stock its 29th biggest holding. EAM Investors LLC’s holdings in Haemonetics were worth $4,071,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Eagle Asset Management Inc. bought a new stake in shares of Haemonetics during the 3rd quarter worth $52,658,000. Teachers Retirement System of The State of Kentucky lifted its stake in Haemonetics by 25.7% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 17,536 shares of the medical instruments supplier’s stock worth $2,010,000 after purchasing an additional 3,587 shares during the last quarter. Zeke Capital Advisors LLC lifted its stake in Haemonetics by 136.8% in the third quarter. Zeke Capital Advisors LLC now owns 6,451 shares of the medical instruments supplier’s stock worth $739,000 after purchasing an additional 3,727 shares during the last quarter. ClariVest Asset Management LLC lifted its stake in Haemonetics by 41.6% in the third quarter. ClariVest Asset Management LLC now owns 61,576 shares of the medical instruments supplier’s stock worth $7,056,000 after purchasing an additional 18,087 shares during the last quarter. Finally, Prudential Financial Inc. lifted its stake in Haemonetics by 8.6% in the third quarter. Prudential Financial Inc. now owns 288,729 shares of the medical instruments supplier’s stock worth $33,082,000 after purchasing an additional 22,853 shares during the last quarter. Hedge funds and other institutional investors own 96.23% of the company’s stock.

HAE has been the subject of several recent research reports. TheStreet downgraded shares of Haemonetics from a “b” rating to a “c+” rating in a research note on Monday, August 20th. Barrington Research reissued a “buy” rating and issued a $127.00 price target on shares of Haemonetics in a research note on Friday, October 5th. Morgan Stanley boosted their price target on shares of Haemonetics from $100.00 to $120.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 8th. Jefferies Financial Group reissued a “buy” rating and issued a $125.00 price target on shares of Haemonetics in a research note on Tuesday, August 7th. Finally, Zacks Investment Research raised shares of Haemonetics from a “hold” rating to a “strong-buy” rating and set a $122.00 price target for the company in a research note on Friday, October 12th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and two have given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $113.20.

Haemonetics stock opened at $110.80 on Friday. The company has a quick ratio of 2.06, a current ratio of 2.92 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $5.73 billion, a price-to-earnings ratio of 50.36, a price-to-earnings-growth ratio of 3.80 and a beta of 1.09. Haemonetics Co. has a twelve month low of $55.84 and a twelve month high of $117.56.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Tuesday, November 6th. The medical instruments supplier reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.54 by $0.02. The business had revenue of $241.58 million during the quarter, compared to the consensus estimate of $233.44 million. Haemonetics had a net margin of 2.26% and a return on equity of 16.04%. The firm’s revenue for the quarter was up 7.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.48 earnings per share. On average, equities analysts anticipate that Haemonetics Co. will post 2.33 EPS for the current fiscal year.

In other news, CFO William P. Mr. Burke sold 841 shares of the company’s stock in a transaction dated Thursday, October 25th. The shares were sold at an average price of $46.76, for a total transaction of $39,325.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Jacqueline Scanlan sold 4,890 shares of the company’s stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $112.19, for a total transaction of $548,609.10. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 62,653 shares of company stock valued at $6,973,391. Insiders own 1.04% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Haemonetics Co. (HAE) Stake Lowered by EAM Investors LLC” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.dailypolitical.com/2018/11/18/haemonetics-co-hae-stake-lowered-by-eam-investors-llc.html.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Featured Article: Investing in Growth Stocks

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.